DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: VYVANSE

Summary for Tradename: VYVANSE

Patents:18
Applicants:1
NDAs:1
Suppliers: see list3
2013 Sales:$1,743,115,000
drug
patent expirations by year for
 VYVANSE

Pharmacology for Tradename: VYVANSE

Clinical Trials for: VYVANSE

Effect of Vyvanse on Driving in Young Adults With ADHD
Status: Completed Condition: Attention Deficit/Hyperactivity Disorder(ADHD)

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Completed Condition: Attention Deficit Hyperactivity Disorder; Sleep

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
Status: Completed Condition: Healthy Volunteers

Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression
Status: Terminated Condition: Bipolar Depression

Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence
Status: Completed Condition: Cocaine Dependence

Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
Status: Completed Condition: Attention Deficit Hyperactivity Disorder (ADHD)

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Completed Condition: Attention Deficit Hyperactivity Disorder

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition
Status: Recruiting Condition: Attention Deficit Hyperactivity Disorder

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity
Status: Terminated Condition: Attention Deficit Hyperactivity Disorder; Glucose Intolerance; Obesity

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
Status: Completed Condition: Attention Deficit/Hyperactivity Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Dec 10, 2007RXNo<disabled><disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Dec 10, 2007RXNo<disabled><disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Dec 10, 2007RXNo7,105,486<disabled><disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Dec 10, 2007RXNo7,223,735<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VYVANSE

Drugname Dosage Strength RLD Submissiondate
lisdexamfetamine dimesylateCapsules20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mgVyvanse2/23/2011

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc